戻る
Akero Therapeutics Inc (AKRO)価格
AKRO 株価推移チャート
AKRO Price
Akero Therapeutics Inc
$54.65
0%
$0
終値： Feb 06, 16:00:00 GMT-5
$54.65
0%
$0
アフターマーケット：Feb 06, 20:00:00 GMT-5
A-
最終スコア
主要データ
前終値
$54.65
始値
$54.52
当日レンジ
$54.42 - $54.82
52週レンジ
$21.34 - $58.4
取引高
11.6M
平均取引高
2.1M
1株当たり利益(TTM)
-3.75
配当利回り
--
時価総額
$4.4B
AKROとは何ですか？
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The company is headquartered in South San Francisco, California and currently employs 74 full-time employees. The company went IPO on 2019-06-20. Efruxifermin (EFX), its lead product candidate for MASH, is being evaluated in three ongoing Phase 3 studies: SYNCHRONY Outcomes in patients with compensated cirrhosis (F4) due to MASH, SYNCHRONY Histology in patients with pre-cirrhotic (F2-F3 fibrosis) MASH, and SYNCHRONY Real-World in patients with MASH (F1-F4). The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH and the SYMMETRY study in patients with compensated cirrhosis due to MASH. EFX is an analog of fibroblast growth factor 21 (FGF21), which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body.
